Increased levels of glycoproteins containing mannose 6-phosphate in human breast carcinomas.
Newly synthesized enzymes destined for lysosomal localization contain mannose 6-phosphate (Man6-P) residues, allowing interaction with Man6-P receptors (MPRs) and subsequent intracellular targeting to the lysosome. In most cultured cells, lysosomal enzymes are rapidly dephosphorylated after targeting, but in some transformed cell lines, these proteins retain the Man6-P marker. To investigate the significance of this in human malignancy, we examined the persistence of the Man6-P marker in human breast biopsy specimens using MPR derivatives as affinity probes. In one approach, extracts of frozen tissue were standardized to protein content, fractionated by SDS-PAGE, immobilized on nitrocellulose, and probed with iodinated MPR. On average, carcinomas contained 4-fold higher levels of Man6-P glycoproteins than did benign tumors or normal breast samples. In about 15% of the carcinomas, levels of Man6-P glycoproteins were highly elevated (7-10-fold). Multiple Man6-P glycoproteins were detected, suggesting a general alteration in the synthesis or processing of many lysosomal enzymes in carcinomas. In a second approach, sections of formalin-fixed breast biopsy specimens were probed with biotinylated MPR. Malignant cells in 25 of 75 carcinomas exhibited granular cytoplasmic staining in what appears to be intracellular vesicles. Staining was specifically inhibited by Man6-P and was not observed in stromal components or lymphocytes. In addition, Man6-phosphorylated proteins were not detected in the 14 normal or benign biopsy samples examined. Staining appeared to be independent of most prognostic factors examined, including p53, cathepsin D, DNA ploidy, and hormone (estrogen and progesterone) receptor status. However, positive staining was significantly associated with high histological and nuclear grades (P < 0.05) and potentially with c-erbB-2 (P < 0.10), suggesting that elevated levels of Man6-P glycoproteins are associated with the more aggressive tumors.
Sleat
D E
DE
Center for Advanced Biotechnology and Medicine, Piscataway, New Jersey 08854, USA.
Chen
T L
TL
Raska
K
K
Lobel
P
P
D000230:Adenocarcinoma / Q000737:chemistry* / Q000378:metabolism; D014408:Biomarkers, Tumor / Q000032:analysis / Q000737:chemistry*; D001940:Breast / Q000737:chemistry; D001943:Breast Neoplasms / Q000737:chemistry* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry* / Q000378:metabolism; D006023:Glycoproteins / Q000737:chemistry* / Q000378:metabolism; D006801:Humans; D008360:Mannosephosphates / Q000032:analysis* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000737:chemistry* / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D017527:Receptor, IGF Type 2 / Q000032:analysis / Q000378:metabolism
D014408:Biomarkers, Tumor; D006023:Glycoproteins; D008360:Mannosephosphates; D009363:Neoplasm Proteins; D017527:Receptor, IGF Type 2; C027693:mannose-6-phosphate